RNS Number : 5821C GSK PLC 28 March 2025

GSK plc (the 'Company') Transaction notification

1.	Details of PDMR/per	f PDMR/person closely associated with them ('PCA')			
a)	Name	Cł	narles Bancroft		
b)	Position/status	Se	enior Independent Non-Executiv	e Director	
c)	Initial notification/ amendment	lni	tial notification		
2.	Details of the issuer, auctioneer or auction		mission allowance market pa monitor	rticipant, auction platform,	
a)	Name	G	SK plc		
b)	LEI	54	93000HZTVUYLO1D793		
3.	(ii) each type of tran	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument		nerican Depositary Shares ('AD IN: US37733W2044	Ss')	
b)	Nature of the transaction	Release of 17,446 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 1,602 notional ADSs for tax and the final release of 15,843 ADSs representing the balance. These ADSs will be held by Charles Bancroft until he retires from the Board. A residual cash payment of 32.60 will be paid to Charles Bancroft.			
c)	Price(s) and volume(s)		Price(s)	Volume(s)	
			38.805	15,843	
d)	Aggregated information	N	A (single transaction)		
	Aggregated volume Price				
e)	Date of the transaction	20	25-03-25		
f)	Place of the transaction	Ne	ew York Stock Exchange (XNYS	3)	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Dr Anne Beal		
b)	Position/status	Independent Non-Executive Director		

Initial notification/	Initial notification			
amendment				
		narket participant, auction platform,		
Name	GSK plc			
LEI	5493000HZTVUYLO1D	793		
Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044			
Nature of the transaction	Release of 1,988 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 1,018 notional ADSs for tax and the final release of 970 ADSs representing the balance. These shares will be held by Dr Anne Beal until she retires from the Board. A residual cash payment of 4.66 will be paid to Dr Anne Beal.			
Price(s) and volume(s)	Price(s) 38.805	Volume(s) 970		
Aggregated information N/A (single transaction)				
Aggregated volume Price				
Date of the transaction	2025-03-25			
Place of the transaction	New York Stock Excha	inge (XNYS)		
	amendment Details of the issuer, auctioneer or auction Name LEI Details of the transact (ii) each type of transhas been conducted Description of the financial instrument Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction Place of the	Details of the issuer, emission allowance mauctioneer or auction monitor Name GSK plc LEI 5493000HZTVUYLO1D Details of the transaction(s): section to be management (ii) each type of transaction; (iii) each date; has been conducted Description of the financial instrument Nature of the transaction Release of 1,988 notion Director Share Allocation those arrangements, the and the final release of shares will be held by DA residual cash payme Price(s) and volume(s) Price(s) Aggregated information N/A (single transaction Aggregated volume Price Date of the transaction 2025-03-25 Place of the New York Stock Exchain		

1.	Details of PDMR/pe	erson closely associated with them ('PCA')			
a)	Name	Dr Hal Dietz			
b)	Position/status	Independent Non-Executive Director			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3	Dotaile of the trans	partian(e), coation to be reposted for (i) each time of instruments			

J.	עם בינוים של היום ווים ווים ווים בינוים ווים בינוים ווים של היום ווים בינוים ווים ווים ווים ווים בינוים בי				
a)	Description of the financial instrument		American Depositary Shares ('ADSs') ISIN: US37733W2044		
b)	Nature of the transaction	Di the an sh	Release of 1,760 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 909 notional ADSs for tax and the final release of 850 ADSs representing the balance. These shares will be held by Dr Hal Dietz until he retires from the Board. A residual cash payment of 38.42 will be paid to Dr Hal Dietz.		
c)	Price(s) and volume(s)		Price(s) 38.805	Volume(s) 850	
d)	Aggregated information	ı N/	A (single transaction)		
	Aggregated volume Price				
e)	Date of the transaction	20	25-03-25		
f)	Place of the transaction	Ne	ew York Stock Exchange (XNYS	5)	

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Dr Jesse Goodman			
b)	Position/status	Independent Non-Executive Director			
c)	Initial notification/	Initial notification			
	amendment				
2.	Details of the issuer auctioneer or auction	r, emission allowance market participant, auction platform, on monitor			
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.		 action(s): section to be repeated for (i) each type of instrument; asaction; (iii) each date; and (iv) each place where transaction(s)			
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044			
b)	Nature of the transaction	Release of 13,924 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 7,082 notional ADSs for tax and the final release of 6,842 ADSs representing the balance. These shares will be held by Dr Jesse Goodman until he retires from the			

		Board. A residual cash payment of 11.64 will be paid to Dr Jesse Goodman.			
c)	Price(s) and volume(s)	Price(s) 38.805	Volume(s) 6,842		
d)	Aggregated information Aggregated volume Price	WA (single transacti	on)		
e)	Date of the transaction	2025-03-25			
f)	Place of the transaction	New York Stock Exc	hange (XNYS)		

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEDFWWEISEDD